Literature DB >> 31063550

Opioid Use and Rate of Nicotine Metabolism Among Pregnant Smokers.

Cheryl Oncken1, Erin L Mead1, Ellen A Dornelas2, Chia-Ling Kuo1, Heather Z Sankey3, Henry R Kranzler4, Sheila Thurlow1.   

Abstract

INTRODUCTION: Smokers who use opioids smoke more cigarettes per day (CPD) than non-opioid users, which could be due to the effects of opioids on nicotine metabolism. Moreover, nicotine metabolism increases during pregnancy, potentially making quitting more difficult for pregnant smokers. We examined nicotine metabolism and its association with opioid use (OU) and CPD in pregnant smokers.
METHODS: We recruited pregnant women who smoked at least 5 CPD for a clinical trial of smoking cessation. Plasma nicotine metabolite ratio (NMR; trans-3'-hydroxycotinine (3HC)/cotinine)-a biomarker of nicotine metabolism-OU (involving methadone, buprenorphine, fentanyl, oxycodone, or tramadol), and CPD were assessed at baseline. We used linear regression to examine the associations between log-transformed NMR, OU, and CPD, adjusting for race/ethnicity and menthol smoking.
RESULTS: Among 129 pregnant smokers, 25 (19%) were opioid users; most were maintained on methadone (n = 14). Compared to non-OU smokers, OU smokers had higher median CPD (10.0 vs. 7.0, p = .0007), serum 3HC (81.0 vs. 42.0 ng/mL, p = .0001), and NMR (0.63 vs. 0.43, p < .0001). In addition, methadone-maintained smokers had a higher median NMR than non-OU smokers (0.66 vs. 0.43, p = .0004). Adjusting for covariates, log-transformed NMR was greater in OU smokers (p = .012), specifically methadone-maintained smokers (p = .024), than non-OU smokers.
CONCLUSIONS: Our preliminary results show that OU is associated with a higher NMR in pregnant smokers. A larger study sample is needed to replicate this finding, examine potential mechanisms, and determine its clinical significance. IMPLICATIONS: Among pregnant smokers, we observed that nicotine metabolism was significantly faster among opioid users-the majority of whom were on methadone maintenance-compared to nonusers, which could have implications for smoking cessation. Further studies are needed to replicate this finding, evaluate potential mechanisms, and determine its clinical significance.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco. All rights reserved.For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31063550      PMCID: PMC7249922          DOI: 10.1093/ntr/ntz073

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  19 in total

1.  Cholesterol detoxification by the nuclear pregnane X receptor.

Authors:  Steven A Kliewer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

2.  The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.

Authors:  Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

3.  Quantitative prediction of CYP2B6 induction by estradiol during pregnancy: potential explanation for increased methadone clearance during pregnancy.

Authors:  Leslie J Dickmann; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-07-19       Impact factor: 3.922

4.  Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha.

Authors:  Masahiro Itoh; Miki Nakajima; Eriko Higashi; Ryoko Yoshida; Kiyoshi Nagata; Yasushi Yamazoe; Tsuyoshi Yokoi
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

5.  Rapid nicotine clearance is associated with greater reward and heart rate increases from intravenous nicotine.

Authors:  Mehmet Sofuoglu; Aryeh I Herman; Haleh Nadim; Peter Jatlow
Journal:  Neuropsychopharmacology       Date:  2012-02-15       Impact factor: 7.853

6.  Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency.

Authors:  Noah R Gubner; Joseph Guydish; Gary L Humfleet; Neal L Benowitz; Sharon M Hall
Journal:  Drug Alcohol Depend       Date:  2017-06-23       Impact factor: 4.492

7.  Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor.

Authors:  Antonia H Tolson; Haishan Li; Natalie D Eddington; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2009-06-11       Impact factor: 3.922

8.  Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation.

Authors:  S Banerjee; G Sindberg; F Wang; J Meng; U Sharma; L Zhang; P Dauer; C Chen; J Dalluge; T Johnson; S Roy
Journal:  Mucosal Immunol       Date:  2016-02-24       Impact factor: 7.313

Review 9.  Variation in CYP2A6 Activity and Personalized Medicine.

Authors:  Julie-Anne Tanner; Rachel F Tyndale
Journal:  J Pers Med       Date:  2017-12-01

10.  CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes.

Authors:  A Joseph Bloom; Maribel Martinez; Li-Shiun Chen; Laura J Bierut; Sharon E Murphy; Alison Goate
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

View more
  2 in total

1.  A Longitudinal Analysis of Nicotine Dependence and Transitions From Dual Use of Cigarettes and Electronic Cigarettes: Evidence From Waves 1-3 of the PATH Study.

Authors:  L Morgan Snell; Andrew J Barnes; Nicole E Nicksic
Journal:  J Stud Alcohol Drugs       Date:  2020-09       Impact factor: 2.582

2.  Pregnant Smokers Receiving Opioid Agonist Therapy Have an Elevated Nicotine Metabolite Ratio: A Replication Study.

Authors:  Henry R Kranzler; Yukiko Washio; Leah R Zindel; Kevin G Lynch; Dennis Hand; Rachel F Tyndale; Cheryl Oncken; Robert Schnoll
Journal:  Nicotine Tob Res       Date:  2020-10-08       Impact factor: 4.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.